These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30788013)

  • 1. Update on Management of Type 2 Diabetes for Cardiologists.
    Qureshi M; Gammoh E; Shakil J; Robbins R
    Methodist Debakey Cardiovasc J; 2018; 14(4):273-280. PubMed ID: 30788013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure.
    Osuna PM; Brown SJ; Tabatabai LS; Hamilton DJ
    Methodist Debakey Cardiovasc J; 2018; 14(4):257-265. PubMed ID: 30788011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.
    Fatima S; Jameel A; Ayesha F; Menzies DJ
    Clin Cardiol; 2017 Nov; 40(11):970-973. PubMed ID: 28841228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 5. How to prevent diabetes-triggered heart disease.
    An S; Zhao B; Zhang X; Liu Q
    Eur J Prev Cardiol; 2018 Nov; 25(16):1789. PubMed ID: 29771157
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of antidiabetes medications: An update.
    Bailey CJ
    Clin Pharmacol Ther; 2015 Aug; 98(2):185-95. PubMed ID: 25820533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure in Type 2 Diabetes Mellitus.
    Kenny HC; Abel ED
    Circ Res; 2019 Jan; 124(1):121-141. PubMed ID: 30605420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D; Htun W; Carrion C; Fonseca VA
    Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?
    Swislocki AL; Jialal I
    Metab Syndr Relat Disord; 2016 Feb; 14(1):3-6. PubMed ID: 26677930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
    Cherney DZ; Udell JA
    Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
    [No Abstract]   [Full Text] [Related]  

  • 17. [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].
    ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa Uva M; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL;
    Kardiol Pol; 2013; 71 Suppl 11():S319-94. PubMed ID: 24297732
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?
    Psaty BM; Fleming TR
    Am J Hypertens; 2019 Sep; 32(10):927-929. PubMed ID: 31175821
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.